Full Breakdown
World’s First Exosome Therapy Administered to Burn Patient in Ontario
6/18/2026, 2:21:06 AM
Groundbreaking Exosome Treatment for a London Burn Victim
In December 2025 a fire broke out in a fraternity house near Western University in London, Ontario, sending five people to hospital. Eighteen-year-old student Kaitlin Jeffrey suffered severe facial and neck burns and was transferred to Hamilton General Hospital’s regional burn centre. Physicians at Hamilton Health Sciences (HHS) administered an experimental exosome therapy, making her the first burn patient globally to receive this treatment.
Background on Exosome Therapy
Exosomes are microscopic particles released by cells that coordinate healing, promote tissue repair, and reduce inflammation. Although studied in laboratory burn models, they had never been applied to a human burn case before this intervention. HHS secured a compassionate-use, no-objection approval from Health Canada to proceed.
Data & Statistics
- Date of incident: December 2025.
- Injuries: Five hospitalized; Jeffrey’s burns involved face and neck.
- Exosome regimen: Two infusions spaced several days apart, each containing one trillion exosomes sourced from the United States.
- Treatment timeline: Transfer to Hamilton General Hospital -> first infusion -> second infusion -> ongoing monitoring.
Official Statements & Responses
Dr. Marc Jeschke, HHS burn surgeon and medical director, said the team’s primary goal was to avoid skin-graft surgery for Jeffrey’s facial and neck injuries, noting that even the most advanced grafts cannot restore skin to its original state and often leave significant scarring. He highlighted that traditional grafts, while life-saving, may compromise appearance. Health Canada’s compassionate-use clearance enabled the therapy’s use. HHS researchers expressed optimism that further study and clinical trials could eventually make exosome therapy a standard option for burn patients in Canada and worldwide.
Implications and Next Steps
Jeffrey described the outcome as a “miracle,” emphasizing that the improvement to her facial skin is helping her move forward despite lingering mental-health challenges. If larger trials confirm these early results, exosome therapy could reduce reliance on skin grafts, lower scarring rates, and improve functional and aesthetic outcomes for severe burn victims. HHS plans formal clinical trials to assess safety, dosing, and efficacy across a broader burn population, a step that could pave the way for regulatory approval and wider adoption in burn centres globally.
Verbatim Quotes
- “My vision for Kaitlin was to avoid skin graft surgery to her face and neck at any cost,” — Dr. Marc Jeschke, Burn Surgeon, HHS
- “You can do the best graft on the planet, but you won't return the skin to normal,” — Dr. Marc Jeschke, HHS
- “But having such good results, particularly to my face, is helping me move forward.” — Kaitlin Jeffrey, Patient
- “ Researchers at HHS hope further study and clinical trials will eventually make exosome therapy a standard treatment option for burn patients in Canada and around the world.” — HHS Research Team